x

Join Advarra

Learn more about our company team, careers, and values. Join Advarra’s Talented team to take on engaging work in a dynamic environment.

See Jobs

Gene Therapy Ready Site Network

Advarra is registered with the NIH as the IBC of record for more than 500 research sites that are vetted and prepared to conduct your next clinical trial.

Join the Gene Therapy Network

Leverage the world’s largest integrated IRB and IBC service combined with the most comprehensive Gene Therapy Ready site network to move your clinical trials forward—faster. 

Gene Therapy Ready Sites:

decorative icon of a certificate signifying training qualifications

Receive complimentary registration with the NIH when Advarra serves as your IBC of record

Decorative Icon Green Brain

Demonstrate expertise and readiness to conduct your trials involving genetically engineered therapies and vaccines

decorative icon of spaceship signifying navigation

Complete study startup 5-6 weeks faster than non-GTR sites and 8-12 weeks faster than sites using a local IBC

Is Your Site Ready?

Research into gene therapy-based treatments and mRNA-based vaccines is accelerating exponentially. Is your research site ready to take advantage of this growing area of clinical trials?

Become Gene Therapy Ready by using Advarra as your registered IBC!

Join Gene Therapy Network

Request a Complete List of Gene Therapy Ready Sites

Finding sites ready to perform gene therapy and mRNA-based drug and vaccine trials just got easier.

Decorative image of a multi-site trial

Turnaround Time

Turnaround can depend on a site’s experience with and preparation for IBC review. Sites in Advarra’s Gene Therapy Ready network have an existing IBC and prior experience with human gene transfer studies. When Advarra is selected as the central IRB and IBC, these sites are often reviewed and approved for a new gene therapy and mRNA vaccine research study in just a few days.

Want to Know More About What an IBC is and When Oversight is Required?